<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343435">
  <stage>Registered</stage>
  <submitdate>6/09/2011</submitdate>
  <approvaldate>15/09/2011</approvaldate>
  <actrnumber>ACTRN12611000983909</actrnumber>
  <trial_identification>
    <studytitle>Puerperal and menstrual bleeding patterns after two types of contraceptive devices fitted during elective cesarean section.</studytitle>
    <scientifictitle>Puerperal and menstrual bleeding patterns after two types of contraceptive devices fitted during elective cesarean section.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>contraception</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Contraception</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>There are a total of three groups in this study (a) Copper containing intra-uterine contraceptive device (IUCD) inserted during cesarean section (C.S.) for future contraception, (b) Levonorgestrel containing device inserted for the same indication and (c) Cesarean section without device insertion. Copper containing contraceptive device is the standard IUD used for birth control while Levonorgestrel containing intra-uterine system (IUS) is a newer intrauterine contraceptive device with a steroid reservoir that releases 20 micrograms of levonorgestrel daily. Insertion during cesarean section, requires one minute to perform  to be removed on patient request or after expiry of the device (5 years for levonorgestrel device, and 10 years for IUCD), however the duration of follow-up in the study is only 18 months.</interventions>
    <comparator>Cesarean section without device insertion.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>peurperal blood loss measurement using suction set during operation and pad weighing thereafter.</outcome>
      <timepoint>40 days after delivery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>menstrual blood loss using self-reported menstrual diary.</outcome>
      <timepoint>1 year after delivery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>healthy women, with full-term pregnancy, undergoing elective cesarean delivery, with no medical problems, normal uterus.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>labor pains, multiple pregnancy, medical problems, uterine pathology.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Mervat Sheikh Elarab Elsedeek Omran</primarysponsorname>
    <primarysponsoraddress>649 Elhoreya street, alexandria, Egypt, 03312</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Mervat Sheikh Elarab Elsedeek Omran</fundingname>
      <fundingaddress>649 Elhoreya street, alexandria, Egypt, 03312</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Alexandria faculty of Medicine, Alexandria University</sponsorname>
      <sponsoraddress>Alexandria faculty of Medicine, Alexandria University,  Elraml station, Alexandria, Egypt, 03312.</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>to test the feasibility, safety, and efficacy of contraceptive devices fitting during elective cesarean delivery as well as the impact of this intervention on peurperal and menstrual blood loss.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The ethics committe of Alexandria faculty of medicine, Alexandria university.</ethicname>
      <ethicaddress>Alexandria faculty of Medicine, Elraml station, Alexandria, Egypt, 03312.</ethicaddress>
      <ethicapprovaldate>20/12/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mervat Sheikh elarab Elsedeek</name>
      <address>649 Elhoreya street, Janaklis, Alexandria,Egypt, 03312</address>
      <phone>00203 5759925</phone>
      <fax>00203 4832363</fax>
      <email>mervatsheikhelarab@yahoo.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mervat Sheikh elarab Elsedeek</name>
      <address>649 Elhoreya street, Janaklis, Alexandria,Egypt, 03312</address>
      <phone>00203 5759925</phone>
      <fax>00203 4832363</fax>
      <email>mervatsheikhelarab@yahoo.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mervat Sheikh elarab Elsedeek</name>
      <address>649 Elhoreya street, Janaklis, Alexandria,Egypt, 03312</address>
      <phone>00203 5759925</phone>
      <fax>00203 4832363</fax>
      <email>mervatsheikhelarab@yahoo.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>